Skye Bioscience, Inc.
SKYE$130M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO16 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
7wMarket Overview
Stock performance and key metrics
SKYE News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Nimacimab injection
Obesity
SBI-100 Ophthalmic Emulsion, 0.5%
Primary Open Angle Glaucoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nimacimab injection | Phase 2 | Obesity | - | - |
SBI-100 Ophthalmic Emulsion, 0.5% | Phase 2 | Primary Open Angle Glaucoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply